Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy
| dc.contributor.author | Coşkunol, İpek | |
| dc.contributor.author | Turan, Onur | |
| dc.contributor.author | Baysak, Ayşegül | |
| dc.contributor.author | Solmaz, Dilek | |
| dc.contributor.author | Can, Gerçek | |
| dc.date.accessioned | 2023-08-11T08:50:54Z | |
| dc.date.available | 2023-08-11T08:50:54Z | |
| dc.date.issued | 2023 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Göğüs Hastalıkları Ana Bilim Dalı | |
| dc.description.abstract | Setting-Objective: In this study, it was aimed to reveal the incidence of tuberculosis development in patients receiving tumor necrosis factor-alpha (TNF-?) blocker therapy, despite tuberculosis chemoprophylaxis. Design: 520 patients who were receiving anti TNF-? treatment in the last 3 years were evaluated retrospectively. Radiological imaging tuberculin skin test (TST), history of tuberculosis, BCG vaccine, chemoprophylaxis administration, used anti TNF-? drugs were recorded. Results: There were 265(51.0%) of the patients with ankylosing spondylitis (AS), 175(33.7%) with rheumatoid arthritis, 35(6.7%) with Crohn's, 10(1.9%) with ulcerative colitis (UC), 21(4.0%) with psoriatic arthritis, 14(2.7%) with psoriasis vulgaris. In total, 455 (79.6%) patients were given INH prophylaxis. Active tuberculosis development was observed in five patients (4: pulmonary,1: extrapulmonary; 3: UC, 2:AS) who all received anti TNF-? treatment (0.96%), infliximab. Three patients had tuberculosis disease in the 6th month, and the other 2 patients in the 5th and 24th month of their anti TNF-? treatments, and two had 9-month, and 1 had 6-month chemoprophylaxis history. Conclusion: The incidence of tuberculosis development in patients treated with anti TNF-? was found to be higher than the general population. In our country, where tuberculosis is still prevalent, patients receiving Anti TNF-? treatment (especially in-fliximab) should be carefully questioned and examined about tuberculosis. | |
| dc.identifier.citation | Coşkunol, İ., Turan, O., Baysak, A., Solmaz, D. ve Can, G. (2023). Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy. African Health Sciences, 23(2), 128-132. https://dx.doi.org/10.4314/ahs.v23i2.14 | |
| dc.identifier.doi | 10.4314/ahs.v23i2.14 | |
| dc.identifier.endpage | 132 | |
| dc.identifier.issn | 1680-6905 | |
| dc.identifier.issn | 1729-0503 | |
| dc.identifier.issue | 2 | |
| dc.identifier.scopus | 2-s2.0-85165941747 | |
| dc.identifier.scopusquality | Q3 | |
| dc.identifier.startpage | 128 | |
| dc.identifier.uri | https://dx.doi.org/10.4314/ahs.v23i2.14 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/11306 | |
| dc.identifier.volume | 23 | |
| dc.identifier.wos | 001039372900014 | en_US |
| dc.identifier.wosquality | Q4 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.institutionauthor | Baysak, Ayşegül | |
| dc.language.iso | en | |
| dc.publisher | Makerere University, Medical School | |
| dc.relation.ispartof | African Health Sciences | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | Attribution 4.0 International | * |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | Anti-TNF-Alpha | |
| dc.subject | Tuberculin Skin Test | |
| dc.subject | Tuberculosis | |
| dc.title | Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy | |
| dc.type | Article |
